Vertex Pharmaceuticals Incorporated
$424.36
$5.49(-1.28%)
Vertex Pharmaceuticals Incorporated
VRTX
$424.36
$5.49(-1.28%)
Vertex Pharmaceuticals Incorporated
VRTX
NASDAQ
$424.36
$5.49(-1.28%)
Chart
Upcoming Earnings
Next report date
Aug 3, 2026
Report period
Q3 2026
EPS Estimate
$4.74
Revenue Estimate
$3.22B
Key stats
52-Week Range$424.36
$362.50
$507.92
Market capitalization
$107.94BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
27.23Basic EPS (TTM)
$15.47Net income (TTM)
$3.95BRevenue (TTM)
$12.04BAvg. volume
1.36MBeta (1Y)
0.30Employees
6.10KMarket capitalization
$107.94BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
27.23Basic EPS (TTM)
$15.47Net income (TTM)
$3.95BRevenue (TTM)
$12.04BAvg. volume
1.36MBeta (1Y)
0.30Employees
6.10KScreener Quick Check
Sign in to check this stock against your screeners
Sign InAbout Vertex Pharmaceuticals Incorporated
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
Website
www.vrtx.comHeadquarters
50 Northern Avenue, Boston, MA, 02210
IPO Date
1991-07-24
Identifiers
ISIN
US92532F1003Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis....
Related Stocks
$56.95
1D:
-0.7%
1Y:
13.8%
US1101221083Healthcare
Mkt Cap
$116.28B
P/E Ratio TTM
16.4
Revenue TTM
$48.19B
Beta
0.26
Earnings TTM
$7.05B
Dividend Yield TTM
4.29%
$295.25
1D:
1.5%
1Y:
-22.6%
US8636671013Healthcare
Mkt Cap
$113.08B
P/E Ratio TTM
33.8
Revenue TTM
$25.12B
Beta
0.81
Earnings TTM
$3.25B
Dividend Yield TTM
1.17%
Dividend Overview
This company does not pay dividends
Financials
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q3 '26
Actual
Estimate
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q3 '26
Actual
Estimate